Remarkably, sotorasib (AMG510), a RAS GTPase family inhibitor, was approved by the US FDA in May 2021 and was the first approved targeted treatment for KRAS G12C-mutated NSCLC [124]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.